On May 28, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of lenalidomide (REVLIMID, Celgene Corporation) in combination with rituximab (RITUXAN, Genentech, Inc.) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) and marginal zone lymphoma (MZL).
The approval is based primarily on results from the randomized, double-blind, Phase 3 Augment study, which evaluated the efficacy and safety of the lenalidomide + rituximab combination versus rituximab plus placebo in patients with previously treated FL and MZL.
Read more about this study in LRF’s Research News section.
“Chemotherapy continues to be a standard of care for indolent forms on NHL, but most patients will relapse or become refractory to their current treatment,” said Meghan Gutierrez, Chief Executive Officer at the Lymphoma Research Foundation. “This approval represents a new therapeutic option for previously treated patients with follicular and marginal zone lymphomas, including those who relapse or no longer respond to initial treatment. We commend the patients and scientists who participated in the clinical study for advancing lymphoma research and treatment.”
For more information on this FDA approval visit the FDA’s website or LRF’s follicular and marginal zone lymphoma learning centers at lymphoma.org/FLFDAUpdates and lymphoma.org/MZLFDAUpdates.
Contact:
Kinya P. Harte
Director of Communications and Marketing
kharte@lymphoma.org
646-465-9107
